In Neurofit's Aβ-induced memory-impairment model, chronic A1070722 treatment produced clear, statistically significant cognitive improvement whereas Aβ-aggregation-focused inhibitors such as scyllo-inositol showed non-significant trend toward recovery. This comparison underscores an important therapeutic insight: amyloid-directed approaches alone offer incomplete rescue, and fuller functional benefit likely requires interventions that act through complementary mechanisms — particularly those modulating the downstream GSK-3/Tau signaling axis. As Alzheimer's pathology reflects multiple converging biological failures, therapeutic strategies that combine amyloid removal with intracellular pathway correction represent a more rational and potentially more effective path toward disease modification.

Our early screening protocol positions A1070722 as a high-confidence comparator, allowing rapid identification of compounds unlikely to withstand Phase II demands.
Combination strategies, pairing amyloid removal with targeted intracellular pathway correction, represent a more comprehensive future direction for Alzheimer's therapy. Compounds such as A1070722 illustrate how downstream GSK-3/Tau modulation can complement amyloid-directed approaches, highlighting the value of multi-mechanism interventions in a landscape where amyloid removal alone is no longer sufficient.